

ATTACHMENT 72



Selected Financial Data - RFP entitled: "Pharmacy Benefit Services for The Empire Plan, Excelsior Plan, Student Employee Health Plan, and NYS Insurance Fund Workers' Compensation Prescription Drug Programs"

**Empire Plan Prescription Drug Program
Selected Financial Data**

MONTHLY PREMIUM RATES

Effective Date of Rate	Empire Plan (1)		Student Employee Health Plan (SEHP)		Excelsior Plan	
	Individual	Family	Individual	Family	Individual	Family
1/1/2020	\$176.26	\$375.05	\$57.76	\$142.71	\$149.82	\$318.79
1/1/2021	\$177.28	\$375.92	\$56.34	\$124.69	\$177.28	\$364.64
1/1/2022	\$190.86	\$419.86	\$59.53	\$157.47	\$133.92	\$253.12
1/1/2023	\$217.72	\$459.12	\$78.29	\$228.36	\$193.60	\$347.15

ENROLLMENT Empire Plan (2)

Year	Active		Retired (3)		COBRA & YAO		Total Contracts
	Individual	Family	Individual	Family	Individual	Family	
2020	104,430	167,642	165,606	102,437	1,185	366	541,667
2021	101,461	161,917	168,144	104,509	1,339	445	537,814
2022	101,228	157,250	170,732	105,371	1,214	370	536,166

ENROLLMENT Excelsior Plan (2)

Year	Active		Retired (3)		COBRA & YAO		Total Contracts
	Individual	Family	Individual	Family	Individual	Family	
2020	163	137	83	47	0	1	432
2021	187	152	88	59	1	2	488
2022	263	267	94	55	1	1	681

ENROLLMENT Student Employee Health Plan (SEHP) (2)

Year	Active			COBRA & YAO		Total Contracts
	Individual	Family		Individual	Family	
2020	4,283	590		173	39	5,084
2021	4,076	559		185	41	4,861
2022	4,289	488		141	28	4,946

- (1) Represents the premium rates for the most common plan design (flexible formulary and speciality drug pharmacy).
- (2) Represents the monthly average "with drug coverage" enrollment for the respective periods.
- (3) Represents all non-actively employed, non-COBRA enrollees, ie., retirees, dependent survivors, preferred list enrollees, vestees, etc.

EXPERIENCE

	2020	2021	2022
Premium	1,832,192,562	1,790,722,415	\$1,933,641,501
Paid Claims (1)	1,851,694,461	1,991,750,552	\$2,021,531,397
Change in Reserves	-\$ 2,586,975	-\$278,187	-\$1,351,849
Incurred Claims	\$ 1,849,107,486	\$ 1,991,472,365	\$ 2,020,179,548
Retention	24,796,882	21,531,469	\$12,541,460
Dividend (Loss)			

- (1) Includes formulary rebates and federal subsidies.